Is there a standard SS-31 protocol?

No. Human studies used different designs for different diseases, and they did not establish one general cycle for compounded SS-31. A real protocol includes the diagnosis, product, route, duration, monitoring, outcomes, and stopping rules. The reviewing provider decides whether treatment is appropriate and sets the individual plan rather than copying a schedule from a trial or seller.

What SS-31 protocol did TAZPOWER use?

TAZPOWER enrolled 12 males with genetically confirmed Barth syndrome. Each participant received 12 weeks of daily subcutaneous elamipretide and 12 weeks of placebo in random order, separated by a four-week washout. Ten participants continued into an open-label extension. That design studied a specific disease and manufactured product; it was not a general wellness cycle.

How long did the SPIMM-301 elamipretide trial run?

The randomized part ran for 24 weeks. SPIMM-301, published as MMPOWER-3, assigned 218 adults with primary mitochondrial myopathy to daily subcutaneous elamipretide or placebo. It did not meet its two main outcomes for walking distance and fatigue. The trial's duration shows what researchers tested, not how long an individual prescription should last.

Is compounded SS-31 the same as Forzinity?

No. Forzinity is a manufactured elamipretide product labeled for people with Barth syndrome who weigh at least 30 kilograms. The compounded SS-31 offered here is different from that FDA-approved product and is not FDA-approved. Its formulation, prescription, and monitoring are individual, so Forzinity's label cannot simply be copied into a compounded plan.

Can an SS-31 trial schedule be used as personal dosing advice?

No. Trial schedules are tied to eligibility rules, a specific product, planned monitoring, and prespecified outcomes. They also include reasons to pause or stop. Removing those pieces leaves only a number and calendar. A licensed provider has to review medical history and other medicines, decide whether SS-31 is appropriate, and set the actual prescription.

Has an SS-31 and MOTS-c protocol been studied in people?

No published human trial has tested SS-31 and MOTS-c together. They are both discussed in mitochondrial medicine, but they act differently and have separate evidence bases. A combined cycle found online is therefore not a tested clinical protocol. A provider would need to evaluate each compound on its own evidence and decide whether either one fits the patient's situation.

SS-31 Protocol: What the Trials Actually Used

An SS-31 protocol is not one standard cycle. In medicine, a protocol is the whole study plan: who receives the drug, how it is given, how long the study runs, what gets measured, and when treatment stops. The human SS-31 studies used different plans for different diseases. The only labeled schedule belongs to Forzinity for people with Barth syndrome who weigh at least 30 kilograms. It is not a ready-made schedule for compounded SS-31 or for general energy and aging goals.

The practical answer is simple: trial records can show how researchers organized treatment. A prescriber still has to decide whether compounded SS-31 is appropriate and what an individual plan should look like.

What an SS-31 protocol includes

SS-31, also called elamipretide, is a four-amino-acid peptide studied at the inner membrane of mitochondria, the parts of cells that make usable energy. The SS-31 product page covers the molecule itself. Here, the important point is what makes a plan medically meaningful.

A proper protocol names the population, product, route, duration, comparison group, check-in schedule, outcomes, and stopping rules. Subcutaneous means injected into the fatty layer just under the skin. A crossover means each participant receives both the study drug and placebo at different times, so the person partly serves as their own comparison.

That is much more information than an online cycle chart gives. A number and a calendar leave out the diagnosis, kidney function, other medicines, monitoring, and the reason to continue or stop.

The TAZPOWER plan was built for Barth syndrome

TAZPOWER enrolled 12 males with genetically confirmed Barth syndrome, a rare inherited condition that disrupts cardiolipin, a fat needed for mitochondrial structure. Participants were randomly assigned to 12 weeks of daily elamipretide injections or placebo, followed by a four-week washout and then 12 weeks on the other treatment. Placebo means an inactive look-alike used for comparison.

The blinded portion did not meet either main goal: six-minute walking distance or a fatigue score. Ten participants then entered an open-label extension, meaning everyone knew they were receiving elamipretide. Eight participants reached week 168, but without a simultaneous placebo group that phase answers a different, less certain question than the blinded phase (Thompson et al., Genetics in Medicine 2021; Thompson et al., Genetics in Medicine 2024).

The FDA label now describes a daily injection under the skin for Forzinity in Barth syndrome. It also changes the labeled amount for some adults with severe kidney impairment. Those specifics belong to one product and one diagnosis; the separate SS-31 dosage guide explains the amounts without turning them into instructions (Forzinity prescribing information, revised September 2025).

SPIMM-301 used a different SS-31 protocol

The official study code is SPIMM-301, published as MMPOWER-3. It enrolled 218 adults with primary mitochondrial myopathy, a group of inherited disorders that impair how muscles make energy. Unlike TAZPOWER, this was a parallel trial: half received daily elamipretide injections and half received placebo for 24 weeks. The groups stayed separate.

Its two main outcomes were walking distance and fatigue. Neither improved versus placebo at week 24 (Karaa et al., Neurology 2023). That matters when reading a protocol. A schedule can be carefully tested without showing the hoped-for result.

Another trial, PROGRESS-HF, used two elamipretide dose groups for 28 days in 71 adults with heart failure. It did not improve the main heart-imaging measure compared with placebo (Butler et al., Journal of Cardiac Failure 2020). Together, these trials show why there is no universal SS-31 cycle: researchers changed the duration, comparison, dose structure, and outcome to match the question.

MOTS-c is sometimes placed beside SS-31 because both are discussed in mitochondrial medicine. They are different peptides, and no human trial has tested a combined schedule. The SS-31 and MOTS-c comparison keeps those evidence bases separate.

What the Forzinity label changes—and what it does not

The FDA granted Forzinity accelerated approval on September 19, 2025, to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. Accelerated approval allows earlier access based on a measure considered reasonably likely to predict clinical benefit; it still requires confirmation. The FDA says the original randomized phase did not show a significant difference in knee strength, while changes appeared during the longer open-label period (FDA Drug Trials Snapshot).

SS-31 through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Forzinity's label does not transfer its schedule, evidence, or Barth syndrome indication to a compounded preparation.

Regulatory status is one fact in the decision. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

As of September 9, 2026, the day this article was written, Forzinity remains on the FDA's ongoing accelerated-approval list, with a confirmatory report due by March 31, 2030. The public record for that 72-week study, called 4TAZPower, lists an estimated 48 male participants with genetically confirmed Barth syndrome and still says “not yet recruiting” (FDA ongoing accelerated approvals, ClinicalTrials.gov NCT07531251).

A separate study published in August 2026 tested 12 weeks of elamipretide in rats with a model of heart failure. It adds animal data about muscle and mitochondria, not a human dosing schedule (Vahle et al., Circulation: Heart Failure 2026).

Why gray-market cycles are guesses

A gray-market schedule often borrows a daily pattern or trial number, then removes the guardrails that gave it meaning. The vial may not match the manufactured product used in the paper. The person following the chart may not resemble the trial population. There may be no baseline check, no planned outcome, and no clinician watching for a reason to stop.

“Cycle” also suggests that a certain number of weeks on and off has been established. The human trials do not support one standard on-off pattern. They studied continuous daily exposure for set research periods, and they reached mixed results. Turning those designs into a repeating wellness cycle is an inference, not evidence.

What a prescriber decides

A sensible clinical plan starts with the goal and the evidence closest to it. The provider then considers medical history, kidney function, current medicines, pregnancy or breastfeeding, whether injections are tolerable, what will be measured, and when the plan will be reviewed. Those details are the protocol. The calendar comes later.

At Promise, a licensed provider reviews every SS-31 request and prescribes only when it is medically appropriate. Not everyone qualifies, and the provider may decline.